Trial Profile
A study of transdermal Sufentanil (NAL1241) for cancer pain
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2016
Price :
$35
*
At a glance
- Drugs Sufentanil (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Therapeutic Use
- 12 Aug 2016 New trial record